Democrats Refuse To Even Talk To the American People Anymore
From SEAL Team Six to KY-4: Ed Gallrein’s Mission to Defeat Thomas Massie
A Quick Bible Study Vol. 320: What the Old Testament Says About Food
Nick Kristallnacht
Nicki Minaj, Amber Rose, and The Supremes Are Liberators for Black Voters
Between Ben-Gurion and Bishop Benjamin
Fatherless Boys and the Invisible World of Misguided Girls
Let Us Not Underestimate the Degree of Moral Decline in America
'The Letter Kills, but the Spirit Gives Life': Procedure, Moral Fragments and...
RINO Sen. Bill Cassidy Loses Historic Senate Primary Race
New Poll Projects Tight Oregon Governor's Race
Driver Rams Pedestrians in Modena, Italy; Eight Injured in Suspected Terror Attack
U.S. Secret Service Seized 14 Skimmers, Stopped $14.5M of Fraud in Houston Area
McMorrow Pushed Water Affordability While Racking Up $3,000 Unpaid Utility Tab at Million-...
USDA SNAP Data Integrity Team Finds About $3B of Fraud Across 20+ States
OPINION

West Virginia on the Right Track to Lower Drug Costs, But is it Enough?

The opinions expressed by columnists are their own and do not necessarily represent the views of Townhall.com.
West Virginia on the Right Track to Lower Drug Costs, But is it Enough?
AP Photo/Matt Rourke

The GOP-controlled House of Delegates in West Virginia recently unanimously passed a bill that would require pharmacy benefit managers (PBM) to share the rebates they receive from drug companies with consumers at the point of purchase. The bill now goes to the state Senate.

Advertisement

Pharmacy benefit managers were created to administer drug benefits for health plans including commercial, employee and retiree plans and Medicare Part D.  In 2003, the PBM industry secured safe harbor status from Congress that exempted them from criminal prosecution for taking rebates from drug manufacturers. 

Essentially, PBMs can collect these kickbacks and give certain medications access to the millions of insured lives they manage over another manufacturer’s products based on how much the companies pay them. The PBMs’ priority shifted from the payer (health plans) to the seller (drug manufacturers) and created a conflict of interest. 

Patients may find the cost of their medications drastically increase due to a change in formulary tiering set by the pharmacy benefit manager. A skewed business practice emerged where PBMs are paid a percentage of the cost of the utilized drugs they manage which increases the compensation they receive for higher-priced drugs. Keep in mind that PBMs do no research and development, manufacturing or distribution. 

The West Virginia bill is admirable in that state legislators want to address the escalating price of prescription drugs and lower the out-of-pocket costs for consumers, but is it enough? AMAC – the Association of Mature Americans, along with a coalition of physician and patient advocates are working together to see the safe harbor status repealed and the middleman money removed completely from the outpatient prescription drug supply chain.

Advertisement

Related:

DRUGS HEALTH CARE

Drug manufacturers’ list prices are negatively affected by the kickbacks they must pay to PBMs. Removing the middleman money and the resulting many billions of dollars saved in drug costs seems like a sensible place to start the forthcoming debate on health care reform.  

Andrew Mangione is Senior Vice President at AMAC Action, the advocacy arm of AMAC – the Association of Mature American Citizens.  AMAC represents more than 2 million members and stands for fiscal responsibility. He writes on health care issues, among other concerns.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement